Biotech Values

[DewDiligence]

Re: PF-06954522, a new oral GLP-1 from PFE

PFE has another oral GLP-1R agonist, PF-06954522, that recently entered phase-1. (PF-06954522 should not be confused with Danuglipron, a/k/a PF-06882961, which is in phase-2 and has been much discussed in the investment community.)

PFE disclosed the existence of PF-06882961 for the first time in the slide set accompanying the 3Q23 CC on 10/31/21—see the bottommost line of slide #7 at https://cdn.pfizer.com/pfizercom/product-pipeline/Pipeline_Update_31OCT2023_0.pdf .

The listing for the phase-1 trial of PF-06882961 is at: https://www.clinicaltrials.gov/study/NCT06003777 .

PF-06882961 is one of the compounds that came out of the 2015 drug-discovery collaboration between PFE and Sosei Heptares (#msg-118817193).